Additional file 2: of Optimising first- and second-line treatment strategies for untreated major depressive disorder â the SUNâşD study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial
- Tadashi Kato (1538845)
- Toshi Furukawa (5500829)
- Akio Mantani (5500817)
- Kenâichi Kurata (5500892)
- Hajime Kubouchi (5500811)
- Susumu Hirota (5500796)
- Hirotoshi Sato (117839)
- Kazuyuki Sugishita (5500823)
- Bun Chino (5500832)
- Kahori Itoh (5500826)
- Yoshio Ikeda (260838)
- Yoshihiro Shinagawa (5500805)
- Masaki Kondo (197045)
- Yasumasa Okamoto (82701)
- Hirokazu Fujita (5500799)
- Motomu Suga (219637)
- Shingo Yasumoto (5500814)
- Naohisa Tsujino (5500802)
- Takeshi Inoue (208656)
- Noboru Fujise (3164064)
- Tatsuo Akechi (417303)
- Mitsuhiko Yamada (113758)
- Shinji Shimodera (306974)
- Norio Watanabe (39913)
- Masatoshi Inagaki (553137)
- Kazuhira Miki (5500808)
- Yusuke Ogawa (5500835)
- Nozomi Takeshima (4433596)
- Yu Hayasaka (4433599)
- Aran Tajika (5500793)
- Kiyomi Shinohara (4433602)
- Naohiro Yonemoto (468815)
- Shiro Tanaka (307051)
- Qi Zhou (7408)
- Gordon Guyatt (56595)
DOIAbstract
Figure S1. Schedule of the assessments. Table S1. Incidence of suicidality, manic switches or any serious adverse events up to week 9 for step 1 randomisation. Table S2. Incidence of suicidality, manic switches or any serious adverse events up to week 25 for step 1 randomisation. Table S3. Two pre-specified subgroup analyses for step 1 randomisation. Table S4. Four pre-specified sensitivity analyses for step 1 randomisation. Table S5. Incidence of suicidality, manic switches or any serious adverse events up to week 9 for step 2 randomisation. Table S6. Incidence of suicidality, manic switches or any serious adverse events up to week 25 for step 2 randomisation. Table S7. Three pre-specified subgroup analyses for step 2 randomisation. (DOCX ...
Add to ORKG